Host Dr. Alan S. Brown is joined by Kevin C. Maki, PhD, FNLA, Chief Science Officer of Biofortis Clinical Research. Dr. Maki will review obesity, metabolic syndrome and type 2 diabetes mellitus as they are all insulin resistant states and are often characterized by atherogenic dyslipidemia or the "lipid triad" of elevated triglycerides, low HDL cholesterol and a predominance of small, dense LDL particles.
Obesity, Diabetes and the Metabolic Syndrome
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Host Dr. Alan S. Brown is joined by Kevin C. Maki, PhD, FNLA, Chief Science Officer of Biofortis Clinical Research. Dr. Maki will review obesity, metabolic syndrome and type 2 diabetes mellitus as they are all insulin resistant states and are often characterized by atherogenic dyslipidemia or the "lipid triad" of elevated triglycerides, low HDL cholesterol and a predominance of small, dense LDL particles.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Engaging Patients and Caregivers About Digital Therapeutics
Beyond Plaques: Current Concepts in Alzheimer’s Pathophysiology
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
Personalizing Care Within the RCC Treatment Paradigm
Collaborative Insights to Solve the Puzzle of Bladder Cancer
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?